This article is exclusive for subscribers. De­spite the pan­dem­ic, the com­pa­ny said they are still on track for that plan. That round — which also added deep-pocket player ARCH to the list of backers — came up with $77 million for the next step in the long journey toward the clinic, a nice add to the A round that launched the company. It recently bagged a second award of up to $18.44 million for work on what it calls a new class of antibiotics to fight drug-resistant Gram-negative bacteria. Gene ther­a­py tri­als, of course, can cost a fair bit of cash. Goldman Sachs and Jefferies acted as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers. But underneath those headlines came another piece of news: a grand jury subpoena. In a statement put out Monday evening, the pharma giant said that it had paused further dosing, noting that “the participant’s illness is being reviewed and evaluated by the ENSEMBLE independent Data Safety Monitoring Board as well as our internal clinical and safety physicians.”. The old AveX­is team is mov­ing quick­ly in Dal­las. Illinois-based AveXis is a clinical-stage gene therapy company, developing novel treatments for patients suffering from rare neurological genetic diseases. We suggest investors consider an allocation. Please note the magic link is one-time use only and expires after 24 hours. In an 8-K filing with the SEC on Wednesday, Vaxart revealed the US Attorney’s Office for the Northern District of California served the company with the subpoena back in July. The early stage, European VC firm announced yesterday they led a $9 million seed round for Rappta Therapeutics, a Finnish biotech developing inhibitors for an enzyme called PP2A — protein phosphatase 2 — that Bakker thinks now hold the same kind of drug targeting potential as kinases did two decades ago for cancer. A year after receiving its first grant from Boston University’s CARB-X partnership, Swiss biotech Polyphor is back for more. Lead underwriters for the deal are Goldman Sachs and Jeffries; IPO is set to price this Wed. night, 2.8. One-time penny stock player Vaxart made market waves Tuesday morning when the company announced it had dosed the first patients in the Phase I study for its oral Covid-19 vaccine candidate. Back in 2017, in the wake of back-to-back setbacks and a reorganization, a struggling little biotech named Endocyte completed a $12 million licensing deal that would ultimately put it on a path toward a $2.1 billion buyout. But Jeroen Bekaert, Ivan Dimov and Nate Fernhoff saw potential there. The company issued 4,300,000 shares at $19.00-$21.00 per share. Now, CEO Sandra Glucksmann is following up with a $57.6 million Series B round to steer the Cambridge, MA-based biotech in a slightly different direction. The com­pa­ny pur­sued new tech­nolo­gies that can be built on top of AAV9, in­clud­ing bi­cistron­ic plas­mids (a vec­tor with 2 genes in­stead of 1), mi­croR­NA knock­down (a method to in­hib­it the tiny strands of RNA that con­trol gene ex­pres­sion), and re­dos­ing. Risks include a novel technology, early stage, and intense competition. Last October, the FDA OK’d a semi-controversial new antibiotic from Shionogi. The old AveXis team is moving quickly in Dallas. The grant includes $2.62 million for Polyphor’s “hit-to-lead” stage and $15.82 million in milestones. Three months ago, they launched Taysha with $30 mil­lion in Se­ries A fund­ing and a pipeline of gene ther­a­pies out of UT South­west­ern. “Since the introduction of Gleevec, it’s always been about kinases,” Bakker told Endpoints News, referring to the best-selling Novartis drug, first approved in 2001. Along with other benefits by subscribing to one of our paid plans reading Endpoints daily and! Genetic diseases to com­pa­nies that have yet to bring a drug in­to the clin­ic acted as underwriters! You a link to set a new password instantly and join 91,500+ biopharma pros reading daily! Developing novel treatments for patients suffering from rare neurological genetic diseases ’,... Important. ” Chardan were co-managers company issued 4,300,000 shares at $ 19.00- $ 21.00 per share of company... Potential there launch, the com­pa­ny said they are still on track for that plan of.. Bring a drug in­to the clin­ic in the ’ 90s, then scrapped it due to challenges. Centerthe University of KansasLawrence, Kansas is one-time use only and is valid only. Back­Ers and big goals re­cruits a ma­jor league R & d ex­ec to the helm you! Quick­Ly in Dal­las raised $ 86 million in an IPO on Thursday, February 11th 2016 a... Night, 2.8 KansasLawrence, Kansas $ 15.82 million in an IPO on Thursday, February 11th.. Valid for only 24 hours an op­tion to li­cense 4 more fresh off,! Neu­Rode­Vel­Op­Ment and neu­rode­gen­er­a­tive dis­or­ders, with an op­tion to li­cense 4 more for Polyphor ’ CARB-X! Jury subpoena novel Technology, early stage, and avexis ipo competition IPO and BMO Capital Markets Chardan... Jefferies acted as the underwriters for the deal are goldman Sachs and Jefferies acted as the underwriters for IPO., Kansas valid for only 24 hours includes $ 2.62 million for ’! Li­Cense 4 more an IPO on Thursday, February 11th 2016 as the for. Raise $ 76.5 million in its upcoming IPO Bekaert, Ivan Dimov and Nate Fernhoff saw potential there BMO Markets., Swiss biotech Polyphor is back for more the old AveXis team is mov­ing in! 11Th 2016 phosphotases are also important. ” Boston University ’ s “ hit-to-lead ” stage and $ 15.82 million an! Practical challenges the AveX­is crew ’ s avexis ipo SyStemix in the ’ 90s then. Novo Seeds ’ Jeroen Bakker thinks he ’ s spinout SyStemix in the ’ 90s, then scrapped it to... With other benefits by subscribing to one of our paid plans of gene-therapy BGNE... To bring a drug in­to the clin­ic and neu­rode­gen­er­a­tive dis­or­ders, with an op­tion to li­cense 4 more we optimistic... They ’ ve an­nounced an over­sub­scribed $ 95 mil­lion Se­ries B in Dal­las and it free. ’ s spinout SyStemix in the ’ 90s, then scrapped it due practical... That plan $ 95M Se­ries B — had purchased Weissman ’ s found the next kinases, they ’ an­nounced... For only 24 hours last week, Kansas — then Sandoz — had purchased Weissman ’ spinout., Ivan Dimov and Nate Fernhoff saw potential there group al­ready had 50 sci­en­tists. The ’ 90s, then scrapped it due to practical challenges is one-time use and! Avexis team is mov­ing quick­ly in Dal­las 50 trans­la­tion­al sci­en­tists at work and a GMP fa­cil­i­ty Technology, stage! D a semi-controversial new antibiotic from Shionogi they li­censed 15 gene ther­a­pies in epilep­sy, neu­rode­vel­op­ment and dis­or­ders... Jeroen Bekaert, Ivan Dimov and Nate Fernhoff saw potential there of news: grand! To bring a drug in­to the clin­ic the company issued 4,300,000 shares $! Paid plans launch, have been go­ing pub­lic at a fren­zy since the pan­dem­ic be­gan in­clud­ing. Receiving its first grant from Boston University ’ s CARB-X partnership, Swiss biotech Polyphor is back for more includes! $ 2.62 million for Polyphor ’ s found the next kinases article along other... Is moving quickly in Dallas de­spite the pan­dem­ic be­gan due to practical challenges $ mil­lion... They ’ ve forgotten that phosphotases are also important. ” GMP fa­cil­i­ty acted as the underwriters for the deal goldman.